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Wound healingImpaired wound healing is an important clinical problem in diabetes mellitus and results in failure to completely
heal diabetic foot ulcers (DFUs), which may lead to lower extremity amputations. In the present study, collagen
based dressings were prepared to be applied as support for the delivery of neurotensin (NT), a neuropeptide that
acts as an inﬂammatory modulator in wound healing. The performance of NT alone and NT–loaded collagenmatri-
ces to treat wounds in streptozotocin (STZ) diabetic inducedmicewas evaluated. Results showed that the prepared
dressings were not-cytotoxic up to 72 h after contact with macrophages (Raw 264.7) and human keratinocyte
(HaCaT) cell lines. Moreover, those cells were shown to adhere to the collagenmatrices without noticeable change
in their morphology. NT–loaded collagen dressings induced faster healing (17% wound area reduction) in the early
phases of wound healing in diabetic woundedmice. In addition, they also signiﬁcantly reduced inﬂammatory cyto-
kine expression namely, TNF-α (p b 0.01) and IL-1β (p b 0.01) and decreased the inﬂammatory inﬁltrate at day 3
post-wounding (inﬂammatory phase). After complete healing, metalloproteinase 9 (MMP-9) is reduced in diabetic
skin (p b 0.05) which signiﬁcantly increased ﬁbroblast migration and collagen (collagen type I, alpha 2 (COL1A2)
and collagen type III, alpha 1 (COL3A1)) expression and deposition. These results suggest that collagen-based dress-
ings can be an effective support for NT release into diabetic wound enhancing the healing process. Nevertheless, a
more prominent scar is observed in diabetic wounds treated with collagen when compared to the treatment with
NT alone.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Diabetes mellitus is an important health problem that affects millions
of people over the world and its prevalence is expected to rise up to
439million patients by 2030 [1]. One severe and chronic complication
of diabetes is the diabetic foot ulcer (DFU) that results from peripheral
neuropathy and impaired wound healing (characterized by chronic
inﬂammation, impaired angiogenesis and decreased collagen produc-
tion). DFUs lead to frequent hospitalizations and in extreme cases, to-diphenyltetrazolium bromide;
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ights reserved.amputations that result in elevated hospital costs and poor quality of
life for patients [2,3].
Recently it has been demonstrated that peripheral nerves and cuta-
neous neurobiology contribute to a correct wound healing process [4].
In DFU, the loss of peripheral sensory and autonomic nerves reduces
the production, and consequently the levels, of neuropeptides that are
important for properwound healing [3]. Neurotensin (NT) is a bioactive
neuropeptide widely distributed in the brain and in several peripheral
tissues [5,6] that acts on immune cells (leukocytes, mast cells, den-
dritic cells and macrophages) and leads to cytokine release and
chemotaxis necessary for a correct immunomodulation response.
In addition, NT affects microvascular tone, vessel permeability,
vasodilation/vasoconstriction and new vessel formation which helps
to improve angiogenesis during wound healing processes [3,7,8].
Some neuropeptides namely, substance P and neuropeptide Y have
been topically applied to improve diabetic wound healing [9,10]. How-
ever, the major problem of topical administration of peptides is their
short half-life and loss of bioactivity in the peptidase-rich wound envi-
ronment [11]. A strategy to overcome this problem is the use of
wound dressings made of biocompatible materials for the sustained
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degradation, wound dressings should also replicate skin characteristics
in order to promote the proliferation and migration of ﬁbroblasts and
keratinocytes, as well as to enhance collagen synthesis, leading to prop-
er healing with low scar formation [12].
After injury, the application of wound dressings based on natural
polymers has been proposed to simulate the original cellular environ-
ment and extracellular matrix (ECM) [13]. Collagen is the most abun-
dant protein of ECM being naturally present in human tissues such as
skin, bones, cartilage, tendon and ligaments [14,15]. This biopolymer in-
teracts with cells and regulates cell anchorage, migration, proliferation
and survival [12]. Furthermore, collagen-based dressings have shown
to promote increase in ﬁbroblast production and stimulate a faster
wound healing [16].
In addition, collagen is biocompatible, non-toxic,with low antigenic-
ity [17] and able to absorb large quantities of wound exudate while
simultaneously preserving a moist environment [18]. Due to its charac-
teristics, it is usually considered as an ideal biomaterial for tissue engi-
neering and wound dressing applications [19]. Its efﬁciency in the
treatment of DFU has also been evaluated. Recent studies comproved
the efﬁcacy of collagen dressings to decrease infection by bacteria and
to favoring granulation tissue formation stimulating a faster wound
healing in DFU patients [16,20–22]. Moreover collagen based dressings
have already been used for the delivery of several bioactive agents.
Different approaches tested so far include the incorporation of glucose
oxidase in a collagen matrix in order to enhance the sustained delivery
of reactive oxygen species (ROS), natural compounds (such as polyphe-
nols), growth factors (such as bFGF), antibiotics (such as doxycycline
and levoﬂoxacin) and ionic silver as an antimicrobial agent [20,23,24].
The aim of this study was to develop and apply wound dressings,
prepared from collagen extracted from mouse tails, for the delivery of
NT into diabetic and control wounds. The in vivo progression of skin
wound healing in both diabetic and control mice was also evaluated.
Moreover, the effect of NT on the production of the inﬂammatory and
collagen when applied in skin wounds alone (in solution) or loaded
into collagen-based dressings was analyzed using a mouse model of
wound healing.
2. Material and methods
2.1. Materials
Ketamine (Clorketam1000)was obtained fromVétoquinol (Portugal)
and xylazine (Rompun) from Bayer HealthCare (Germany). NT was pur-
chased from Bachem (Switzerland). The antibodies against TNF-α and
MMP-9 were purchased from Cell Signaling Technology (USA) and the
antibody against actin was purchased from the Millipore Corporation
(USA).
2.2. Preparation of collagen dressing
Collagen isolation and preparation were carried out following the
procedures from Espinosa et al. [43]. Brieﬂy, collagen dressings were
manufactured from type I collagen isolated from mouse-tail tendons.
Mouse tails were washed, and disinfected (2% sodium hypochlorite)
and the tendons were dissected and cut into small pieces. After, they
were suspended in 0.5M acetic acid (4°C during 24h) and the suspen-
sion was centrifuged. The supernatant collagen was dissolved in 0.1M
acetic acid and poured in tissue culture dishes, frozen at −20 °C and
freeze-dried to yield collagen dressings. The dressings were then
rehydrated and cross-linked with glutaraldehyde (0.02%, 4 °C dur-
ing 24 h). Several washes with water were performed to remove
glutaraldehyde residues that did not react during the crosslinking.
Collagen dressings were cut in circular pieces with 6 mm of diameter
and then sterilized with ethylene oxide.2.3. Cell culture
Mouse leukaemic monocyte macrophages (Raw 264.7) and human
keratinocyte (HaCaT) cells were cultured in DMEM medium, pH 7.4,
supplemented with 10% heat inactivated fetal bovine serum (FBS),
3.02 g/l sodium bicarbonate, 30 mM glucose, 100 U/ml penicillin, and
100 μg/ml streptomycin, at 37 °C in a humidiﬁed incubator containing
5% CO2. Sub-culturing was performed according to ATCC recommenda-
tions. Raw 264.7 and HaCaT cell lineswere purchased fromATCC (num-
ber TIB-71) and CLS (number 300493), respectively.
2.4. Scanning electron microscopy (SEM)
Collagen samples were saturated with the DMEM medium before
being placed to 96-well plates. Raw 264.7 (3 × 104 cells/well) and
HaCaT (1.5×104 cells/well) cells were seeded individually onto the sur-
face of the collagen samples with 200μl of DMEM. After 24, 48 and 72h
of incubation, the cells on thematerials were prepared for SEM. At each
timepoint, the sampleswith adherent cellswerewashedwith 0.1Mphos-
phate buffer and ﬁxed with 2% (v/v) glutaraldehyde in 0.1 M phosphate
buffer for 4h, at 4°C. After, theywerewashedwith 0.1M phosphate buffer
and dehydrated by different percentages of alcohol (50%, 75%, 95% and
100%). Finally, samples were coated with gold (approximately 300Å) in
an argon atmosphere and SEM micrographs were obtained at 15 kV
(JEOL, model JSM-5310, Japan).
2.5. In vitro evaluation of collagen dressing's biocompatibility
Raw 264.7 (3×104 cells/well) and HaCaT (1.5×104 cells/well) cells
were plated individually in 96-well plates with 200 μl of DMEM above
previously sterilized collagen dressings. After 24, 48 and 72h of incuba-
tion, the medium was removed and 200μl of 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) solution (0.5 mg/ml) was
added to each well. The plates were further incubated at 37 °C for 4 h,
in a humidiﬁed incubator containing 5% CO2. After this period, 200 μl
of acidic isopropanol (0.04N HCl in isopropanol) was added. Formazan
produced was quantiﬁed using an ELISA automatic microplate reader
(SLT, Austria) at 570 nm, with a reference wavelength of 620nm. Each
sample was analyzed in duplicate.
2.6. NO production — Griess method
Raw 264.7 (3 × 104 cells/well) cells were plated in 96-well plates
with 200 μl of DMEM, above previously sterilized collagen dressings.
After 24, 48 and 72h of incubation, 170 μl of medium supernatant was
mixed with an equal volume of Griess reagent (1% sulfanilamide, 0.1%
N-1-naphthelenediamine dihydrochloride in 2.5% phosphoric acid).
After 30min of incubation in the dark, the absorbance was measured
at 550 nm in a microplate reader (SLT, Austria). Nitrite concentration
was calculated from a previously obtained nitrite standard curve.
2.7. In vivo wound closure
Male C57BL/6 mice (Charles River Corporation Inc., Barcelona,
Spain) weighing 25–30 g were used in this work. The animals were
maintained at normal room temperature (22–24 °C) on a 12 h light/
dark cycle, with free access to commercial pellet diet and water. After
the wounding procedure, the animals were kept in individual cages. All
experiments were conducted according to the National and European
Community Council directives on animal care.
Diabetes was induced by intraperitoneal injections of STZ (50mg/kg
bodyweight), in citrate buffer pH4.5, during ﬁve consecutive days. Four
days after diabetes induction, blood glucose levels were measured by
the Accu-Chek Aviva glucometer (Roche Diagnostics, Germany). The
animals with blood glucose levels higher than 300mg/dl were consid-
ered diabetic. Mice were anesthetized by intraperitoneal injection of
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control and diabetic mice was shaved and two 6mm diameter full-
thickness wounds were created with a biopsy punch.
For each animal, two wounds were performed: one in a top position
(closer to the neck) and other in a bottom position (closer to the tail).
Each animal was randomly distributed in groups and identiﬁed by a
number (1, 2, 3, etc. in each group). Animalswith odd numbers received
treatment in the top wound while those with even number received
treatment in the bottom wound (to minimize area dependent healing
proﬁles).
C57BL/6 mice were divided into six groups of treatment for control
(non-diabetic) and other six similar groups for diabetic mice — three
groups for day 3 (d3) (I, II, III) and three similar groups for day 12
(d12) (IV, V, VI): groups I and IV were treated with collagen dressings
alone, groups II and Vwith topical application of 50μg/ml NT andgroups
III and VI with 50 μg/ml NT–loaded collagen dressings. For each animal
one of the wounds worked as control (PBS application only) and the
other received treatment. For each group, an average of 5 to 8 animals
were included, either for control or diabetic mice. The dried type 1 col-
lagen foams were applied over the wounds and wetted with 5μl of PBS
or NT solution (50μg/ml) to originate hydrogels. By visual inspection it
was possible to observe that the dressings persist into the wound ap-
proximately until days 6–7. The progress ofwoundhealingwas evaluat-
ed periodically by acetate tracing till day 12. Topical application of PBS
or NT (alone or loaded into the prepared collagen dressing) was per-
formed daily. At day 3 (d3) or after complete healing (fd), C57BL/6
mice were sacriﬁced and around 2mm of tissue and skin surrounding
the wound were harvested. Complete healing day varies between
days 13–16 for control mice and days 14–16 for diabetic mice. These
time points were chosen to evaluate the inﬂammatory (day 3) and the
proliferating/remodeling (fd) phases of wound healing.2.8. Real time RT-PCR
Total RNA was isolated from skin samples with the RNeasy Mini Kit
according to themanufacturer's instructions (Qiagen, USA). First strand
cDNAwas synthesized usingHigh Capacity cDNAReverse Transcription.
Then, real-time RT-PCRwas performed in a BioRadMy Cycler iQ5. Prim-
er sequences are given upon request. Gene expression changes were
analyzed using iQ5 Optical system software v2. The results were nor-
malized using a housekeeping gene, TATA box binding protein (TBP),
which was previously validated in our lab. Quantitative RT-PCR results
were analyzed through delta CT calculations.2.9. Western blotting
Skin tissue lysate was homogenized in RIPA buffer (50mM Tris HCl
pH8, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS,
2mM EDTA, protease inhibitor cocktail, phosphatase inhibitor cocktail
and 1mM DTT). Protein concentration was determined using the BSA
method and the skin lysates were denatured at 95°C, for 5min, in sam-
ple buffer. 40 μg of total protein were resolved on 12% SDS-PAGE and
transferred to PVDF membranes. The membranes were blocked
with 5% fat-free dry milk in Tris-buffered saline containing 0.1%
(v/v) Tween 20 (TBS-T), for 1 h, at room temperature. After blocking,
membranes were incubated with primary antibodies against TNF-α
(1:500), and MMP-9 (1:500), overnight at 4 °C. After incubation, mem-
branes were washed and incubated for 1 h at room temperature, with
anti-rabbit antibody (1:5000), or anti-mouse antibody (1:5000). The
membranes were exposed to the ECF reagent followed by scanning on
the VersaDoc (Bio-Rad Laboratories, Portugal). For normalization,
the membranes were reprobed with an anti-actin antibody (1:10000).
The generated signals were analyzed using the Image-Quant TL
software.2.10. Hydroxyproline content
This analysis was performed using a Hydroxyproline Assay Kit
(Sigma Aldrich). Brieﬂy, 10 mg of skin tissue were homogenized in
100 μl of water and hydrolyzed with HCl 12M at 120 °C for 3h. 25 μl of
the supernatant were transferred to 96-well plate and evaporated in
the incubator at 60 °C till total dryness. After, 100 μl of the Chloramine
T/Oxidation Buffer and 100 μl of the Diluted DMAB Reagent were
added to each sample and incubated for 90min at 60 °C. Quantiﬁcation
was performed using an ELISA automaticmicroplate reader (SLT, Austria)
at 560 nm. Hydroxyproline content was calculated from a previously
obtained hydroxyproline standard curve.2.11. Histopathological analysis
For histological preparations, the skin was ﬁxed in 10% neutral
buffered formalin and then embedded in parafﬁn. Skin tissues were
sectioned in 3 μm thickness slices for histopathological examination
by hematoxylin/eosin (H&E) and for collagen formation by Masson's
Trichrome staining. The stained sections were observed with a micro-
scope Nikon H600L with Digital Camera DXM 1200F (Nikon, Germany).
Analysis of stained skin sections was performed by an experienced
pathologist.2.12. Statistical analysis
Results are expressed as mean± SEM (Structural equation model-
ing). Statistical analysis was performed using one-way ANOVA followed
by Tukey's multiple comparison tests or through the unpaired and
paired t tests by GraphPad Prism (GraphPad Software, Inc., San Diego,
CA, USA) and p values lower than 0.05 were considered statistically
signiﬁcant.3. Results
3.1. In vitro biocompatibility of collagen dressings
SEM analysis show that both Raw 264.7 and HaCaT cell lines adhere
to the collagen dressing surfaces without apparent change in their
morphology (Fig. 1A).
There was also no signiﬁcant difference in the viability of macro-
phages, Raw 264.7, after exposure to collagen dressings during 24, 48
and 72h, and when compared to control, as shown in Fig. 1B. However,
the viability of HaCaT is signiﬁcantly increased after contact with the
collagen dressings for 24 and 48h (Fig. 1C). NO is produced by macro-
phages in response to inﬂammatory stimuli. The production of nitrites,
the ﬁnal stable breakdown product of NO, measured after exposure of
the cells to the collagendressings (Fig. 1D)was not signiﬁcantly affected
when compared to control.3.2. In vivo wound healing experiments
Fig. 2 shows the effect of the different topical treatments studied: NT
alone, collagen dressings alone and NT–loaded collagen dressings both
in control (A) and diabetic (B) mice. PBS was applied in non-treated
wounds. For control mice, no major differences were veriﬁed among
the treatments (Fig. 2A). However, in diabetic mice, signiﬁcant differ-
enceswere observed after day 3 post-wounding,whereNT alone reduced
diabetic wound sizes by 11% (p b 0.05) and NT–loaded collagen by 17%
(pb0.001), compared to the PBS treatedwounds (Fig. 2B). Collagen treat-
ed wounds achieved the signiﬁcance only at day 5, by 18% compared to
control wounds.
Fig. 1. SEMmicrographs for non-loaded collagen foam structures and/or in contact with Raw 264.7 and HaCaT cells obtained by freeze-drying (A). Inner images represent magniﬁcations.
Cell viability of Raw (B) and HaCaT (C) cells in the presence of collagen foams, during 24, 48 and 72h. NO production in Raw cells (D). Results are presented asmean±SEM of three to six
independent experiments.
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In order to address the pattern of cytokine expression in untreated
(d0) or treated wounds at day 3 post-wounding and after completeFig. 2. Wound size for collagen, NT and NT–loaded collagen foam treatments in control
(A) or diabetic (B) mice. The wound size was determined at days 0, 1, 3, 5, 8, 10 and 12
post-wounding. Results are presented as mean±SEM of ﬁve to twenty four independent
experiments. *pb0.05 collagen compared to PBS, **pb0.01 collagen compared to PBS,
*** p b 0.001 collagen compared to PBS, ## p b 0.01 collagen + NT compared to PBS,
### p b 0.001 collagen + NT compared to PBS, $ p b 0.05 NT compared to PBS, $$
p b 0.01 NT compared to PBS.wound healing (fd), gene expression of inﬂammatory cytokines (TNF-
α and IL-1β), MMP-9, TGFβ1, TGFβ3 and several types of collagen
genes (COL1A1, COL1A2, COL3A1) was measured and the results are
presented in Fig. 3A–P. Gene expression for IL-6, KC and growth factors
(EGF, VEGF and PDGF) was also performed, however few differences
were observed and consequently they are presented in Supplementary
Fig. S1.
In unwounded skin (day 0, baseline), and when comparing with
control mice, all the mRNA measured for the inﬂammatory cytokines
and MMP-9 were signiﬁcantly increased in the skin of diabetic animals
(Fig. 3A–F). On the other hand, the expression of TGFβ3 and all types of
collagen genes analyzed was signiﬁcantly reduced (Fig. 3K–P).
At day 3 post-wounding, NT alone stimulated the expression of TNF-
α (pb0.01), TGFβ1 (pb0.05) and all types of collagen (pb0.01) in dia-
betic mice while, in control, IL-1β expression and TGFβ1 expression are
decreased (pb0.01) (Fig. 3A, G, K, M, O). For instance, NT–loaded colla-
gen reduced the expression of inﬂammatory cytokines TNF-α
(pb0.01), and IL-1β (pb0.01) (Fig. 3A and C). COL1A2 was signiﬁcantly
increased (p b 0.01) in diabetics while in controls all types of collagen
are reduced (pb 0.01) (Fig. 3K, M and O). Collagen alone did not affect
inﬂammatory cytokine expression either in diabetic or control skin,
while in diabetics the MMP-9 expression is reduced (p b 0.001) and
TGFβ1 (p b 0.05) and TGFβ3 (p b 0.01) are signiﬁcantly stimulated. In
control mice, expression of VEGF is signiﬁcantly stimulated (p b 0.05)
and COL1A1, COL2A1 and COL3A1 are reduced (p b 0.05; p b 0.01;
pb0.001, respectively) (Fig. 3G, I, K, M and O).
After complete healing (fd), NT alone and NT–loaded collagen re-
duced signiﬁcantly the expression of TNF-α (p b 0.001) and MMP-9
(p b 0.01) in control skin. However both treatments increased signiﬁ-
cantly the expression of TNF-α (p b 0.05) and reduced the expression
ofMMP-9 (pb0.001) in diabetic skin (Fig. 3B and F).Moreover, all treat-
ments stimulated signiﬁcantly the expression of TGFβ1, COL1A1,
COL1A2 and COL3A1 in control skin. However, NT alone reduced the ex-
pression of COL1A1 (p b 0.05) in diabetic skin while collagen alone or
combined with NT signiﬁcantly increased COL1A2 and COL3A1 expres-
sion (Fig. 3H, L, N and P).
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Western blots were performed to evaluate the protein expression in
the skin at the wound site (Fig. 4). At day 0, MMP-9 is signiﬁcantlyFig. 3.The gene expression proﬁle of TNF-α, IL-1β, MMP-9, TGFβ1, TGFβ3, COL1A1, COL1A2 and
or totalwoundhealingday (fd) (B, D, F, H, J, L, N and P) postwounding. Results are presented asm
&& p b 0.01 compared with PBS d3, &&& p b 0.001 compared with PBS d3, *pb 0.05 compared w
compared with diabetic PBS d3, §§ p b 0.01 compared with diabetic PBS d3, # p b 0.05 compare
with diabetic PBS fd.increased (pb0.05) in non-treated diabetic skinwhen compared to con-
trol. In contrast, at day 3, NT–loaded collagen signiﬁcantly reduced
MMP-9 (pb0.05) protein levels and increased signiﬁcantly the protein
expression of TNF-α (p b 0.05) in diabetic skin. Moreover, collagenCOL3A1 in skin biopsies before and after treatments, at either day 3 (A, C, E, G, I, K,M andO)
ean±SEMofﬁve to eighteen independent experiments. & pb0.05 comparedwith PBS d3,
ith PBS fd, **p b 0.01 compared with PBS fd, ***pb 0.001 compared with PBS fd, § p b 0.05
d with diabetic PBS fd, ##p b 0.01 compared with diabetic PBS fd, ###p b 0.001 compared
Fig. 3 (continued).
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healing (fd), NT–loaded collagen dressings signiﬁcantly reduced MMP-
9 protein expression comparingwith PBS in diabetic skin. In addition, an
overall increase in MMP-9 expression was observed at the ﬁnal day as
compared to day 3 post-wounding. Nomajor differenceswere observed
in VEGF protein expressionwith all treatments and time points. In addi-
tion, TNF-α protein expressionwas not detected by western blot analy-
sis after complete healing (fd).3.5. Hydroxyproline content at the wound site
Hydroxyproline levels were measured to evaluate collagen de-
position, in both unwounded and wounded, treated and non-treated
wounded skin (Fig. 5). In unwounded skin, hydroxyproline levels were
signiﬁcantly decreased (pb0.05) in diabeticmice comparingwith control
skin. At day 3 post-wounding, no differences were observed with the
different treatments. However treatments with collagen (with and
Fig. 4. Protein expression of TNF-α and MMP-9 in unwounded skin (day 0) or after treatments, at either day 3 or total wound healing day (fd). Results are presented as mean± SEM of
three to ﬁve independent experiments. § p b 0.05 compared with PBS d3, * p b 0.05 compared with diabetic PBS d3, #p b 0.05 compared with diabetic PBS fd.
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content in control skin after complete healing (fd). The same effect was
observed for NT–loaded collagen in diabetic skin.
3.6. Histopathological analysis of the wound
We performed the histopathological analysis (H&E and Masson's
Trichrome staining) of unwounded and wounded control and diabetic
skin treated with collagen or NT or NT–loaded collagen (Fig. 6A and
B). In unwounded diabetic skin, the thickness of the epidermis (that in-
cludes stratus lucidum, epithelial layers and basal layer) is increased
compared to control skin. At day 3 post-wounding, all the treatments
stimulated an increase in the epidermis thickness. The most signiﬁcant
epidermal thickness was found in the non-loaded and NT–loaded colla-
gen treatments in diabetic skin (Table 1).
A speciﬁc re-epithelialization proﬁle was observed: in control mice,
re-epithelialization occurred from bottom to top with basal cells in the
epidermis covering the scar; in diabetic mice, the re-epithelializationoccurred over the granulation inﬂammatory tissue while it was suffer-
ing repair, without correlation with the treatments and in both groups
(Table 1).
At day 3 post-wounding, none of the treatments affected the num-
ber of polymorphonuclear leukocytes (PMN) in control skin, however
in diabetic skin, these inﬂammatory cells were less recruited to the
wound site treatedwith collagen alone, NT alone or NT–loaded collagen
compared with the PBS (Table 3). No plasma cells were observed either
in control or in diabetic skin. However, less ﬁbrin and a higher number
of ﬁbroblasts were observed at the wound site after treatments in
diabetic skin. In addition, more loose collagen was observed in NT and
NT–loaded collagen treated skin either in control or diabetic wounds.
After complete healing (fd), epidermal thickness was similar either
in control or diabetic skin (Table 2). In addition, inﬂammatory cells
(PMN and plasma cells) were not present at the wound site either in
control or diabetic skin treated or non-treated, with exception of lym-
phocytes that persisted in diabetic treated skin (Table 4). No ﬁbrin
was observed either in control or diabetic skin. There was increased
Fig. 5.Hydroxyproline content levels in unwounded skin (d0) or after treatments, at either day 3 or total wound healing day (fd). Results are presented as mean±SEM of four to six in-
dependent experiments. *p b 0.05 compared with PBS fd.
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treatments followed by collagen and NT treatments in diabetic skin. In
addition, more loose collagen is present in NT and NT–loaded collagen
treated diabetic skin compared with PBS, and the scar is more pro-
nounced in collagen than in NT treated skin.
A summary of cytokine expression and corresponding cell type pro-
duction, in wounded control and diabetic skin, at either day 3 post-
wounding or total wound healing day, is represented on Table 5.
4. Discussion
Treatment, in the particular case of DFUs, should actively promote
wound healing by correcting the expression of biological factors in-
volved in the healing process, namely neuropeptides. Nabzdyk and co-
authors [25] veriﬁed that in DFU, neuropeptides such as substance P
and neuropeptide Y control cytokine release from leukocytes and affect
endothelial cell function. In the present study,we evaluated the effect of
the topical application of NT and NT–loaded collagen in control and di-
abetic wound healing, using a full skin thickness wound mouse model.
Non-loaded collagen and PBS alone were also studied for comparison.
Collagen was used as support for NT as an alternative to facilitate the
application of the neuropeptide into thewound site and also to evaluate
its capacity to sustain its delivery and to avoid biodegradation. This
biopolymer has been frequently used in as wound dressing material to
accelerate healing [26,27]. Among other advantages it has a prominent
role to maintain the biological and structural integrity of the extracellu-
lar matrix (ECM) [28].
Results for the in vitro biocompatibility of collagenwith cells present
in skin, namely macrophage Raw 264.7 and keratinocyte HaCaT cell
lines showed that the materials prepared in this work were non-toxic
against these cell lines (up to 72 h) when compared with control cells
(without collagen). The viability of HaCaT cells was even signiﬁcantly
increased after 24 and 48 h in contact with collagen. SEM analyses
showed that both macrophage Raw 264.7 and keratinocyte HaCaT
cells adhere perfectly to collagenwithout apparent change in theirmor-
phology. Similar results were observed by Yahyouche and co-authors,
[29] which reported that Raw 264.7 macrophages attached to collagen
scaffolds, proliferated and aggregated into it (similarly to our SEM im-
ages). Moreover, in another formulation (nanoﬁbers) collagen showed
to have good adherence after contact with keratinocyte cell line NHEK
[30].
Wound closure results showed that the topical application of NT
reduced signiﬁcantly the wound area in either control and diabetic
mouse skin compared with PBS treated wounds. These results are in
agreement with previous data reported in the literature showing that
different neuropeptides, namely substance P, induce diabetic wound
healing [9,31,32]. Moreover, NT–loaded collagen dressingswere slightly
more effective in reducing wound area, especially in diabetic micealready at day 3 post-wounding. These results suggest a synergistic
behavior between the bioactivity of NT alone and collagen dressing
properties. All the treatments lead to total healing, however larger
scars were developed over diabetic wounds that were treated with
collagen dressings.
An overexpression of inﬂammatory cytokines (IL-1β) and matrix
metalloproteinases (MMP-9) was observed in unwounded diabetic
skin which is in agreement with previously reported data [33]. On
the contrary, the expression of TGFβ3 and all of the collagen genes
analyzed decreased in diabetic skin when compared to control. This
may suggest a decrease in the capacity of diabetic mouse skin to pro-
duce essential components of the skin matrix that would guarantee
correct healing [34]. For instance, a decrease in the migration of ﬁbro-
blasts can lead to a decrease in COL1A1, COL1A2 and COL3A1 levels
and justify the lower amount of collagen deposited as observed from
the hydroxyproline assay results. Similar results were observed by
Black and co-authors [35] which reported a decrease by 40% in the de-
position of collagen in type 1 diabetes and its inﬂuence in the wound
healing process.
The inﬂammatory phase is an important step in diabetic wound
healing that frequently becomes stalled promoting a pro-inﬂammatory
status that originates chronic non-healing diabetic ulcers. TNF-α and IL-
1β are inﬂammatory cytokines involved in the recruitment of cells, such
as neutrophils and macrophages to the wound site, to stimulate the im-
mune response. In the skin, TNF-α produced by inﬂammatory cells and
ﬁbroblasts stimulates adhesion molecules and chemokines leading to
the attachment of inﬂammatory cells to vessels, rolling, migration, and
eventually chemotaxis into the skin [33]. In addition, IL-1β, produced by
macrophages, ﬁbroblasts, keratinocytes and epithelial cells is also an im-
portant player in the early phase of inﬂammation and in the wound
healing process [36]. In the present work, the inﬂammatory phase,
whichwasmonitored at day 3,was characterized by a decrease in the ex-
pression of IL-1β in control mice after treatment with NT and NT–loaded
collagen, suggesting a decrease in the inﬂammatory status, which pro-
motes healing. However, in diabetic mice, NT stimulated an increase of
the TNF-α gene expression while NT–loaded collagen led to a decrease
in the protein expression of this inﬂammatorymarker. In addition, all of
the treatments that were studied decreased the recruitment of inﬂam-
matory cells to the wound site when compared to control. This can sug-
gest that the high expression of TNF-α at day 3, in diabetic mice, is not
only produced by the inﬂammatory cells present in the wound site but
also by other cells, such as ﬁbroblasts and other skin cells. These results
can justify the contraction of the wound, stimulation of granulation
tissue formation and a faster re-epithelialization of the wound site
when NT–loaded collagen is applied. Consequently this treatment has
a potential positive effect in the early phases of wound repair. Similar
resultswere previously obtained in our groupusingNT–loaded chitosan
based derivatives as wound dressings [37].
Fig. 6.Histopathological analysis of hematoxylin and eosin (H&E) (A) andMasson's Trichrome (B) stainings for control and diabeticmouse skin, untreated or treatedwith collagen, NT and
NT–loaded collagen foams (magniﬁcation 100×). Wounds are in continuumwith preserved skin. Representative images of three skin staining were analyzed. a) Less inﬁltrated PMN and
lymphocytes in the granulation tissue after collagen, NT orNT–loaded collagen application in diabeticmice, at day 3 post-wounding; b) increased collagen deposition inNT andNT–loaded
collagen treatedwounds in diabeticmice, at day 3 post-wounding. c) Increased collagen deposition inNT–loaded collagen treatedwounds in diabeticmice at totalwoundhealing day (fd).
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Table 1
Histological analysis of unwounded skin and in the presence of NT, collagen and NT–loaded collagen dressing treated wounds at day 3, by H&E staining.− absence or no alterations, +
presence b10%, ++ presence 10%–50%, +++ presence N 50%, na— not applicable.
Skin (d0) Day 3
PBS Collagen NT NT–loaded collagen
Control Diabetic Control Diabetic Control Diabetic Control Diabetic Control Diabetic
Epidermis thickness
– Stratus lucidum − + − + ++ +++ − ++ ++ +++
– Epithelial layers − + − + ++ +++ − ++ ++ +++
– Basal layer − + − + + ++ − ++ + ++
Wound area (mm2) 27.67±3.1 26.66±2.7 29.6± 0.19 26.98±0.41 23.99±0.37 24.05±0.32 25.54±0.31 23.83±0.24 24.05± 0.22 22.34± 0.18
Re-epithelialization
– From bottom na na + − + − + − + −
– Top cover na na − + − + − + − +
Table 2
Histological analysis of skin in the presence of NT, collagen andNT–loaded collagen dressings treated control and diabeticwounds after complete healing (fd), byH&E staining.+ presence
b10%, ++ presence 10%–50%, +++ presence N50%.
Complete wound healing (fd)
PBS Collagen NT NT–loaded collagen
Control Diabetic Control Diabetic Control Diabetic Control Diabetic
Epidermis thickness
– Stratus lucidum + ++ +++ +++ ++ +++ +++ +++
– Epithelial layers + ++ +++ +++ ++ +++ +++ +++
– Basal layer + ++ ++ +++ ++ +++ ++ +++
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observed for the NT–loaded collagen treated wounds can contribute to
the resolution of the persistent inﬂammation. MMP-9 is produced
by several different types of cells in the skin, including ﬁbroblasts,
keratinocytes, macrophages and endothelial cells [38]. However, no dif-
ferences were veriﬁed in MMP-9 protein expression after NT–loaded
collagen treatment.
Furthermore, TGFβ1 and TGFβ3 are signiﬁcantly increased after
collagen and NT treatments alone, however no signiﬁcant differ-
ences were observed when NT–loaded collagen was also used as
treatments in diabetic mice. This result reinforces the fact that cells
(besides inﬂammatory cells) may contribute to the resolution of
inﬂammation. The TGF-β family of proteins attracts macrophages
into the wound area and stimulates them to produce additional cyto-
kines, to enhance ﬁbroblast and smooth muscle chemotaxis and to
modulate collagen expression and consecutively scar formation [39].
Type I collagen is the most expressed collagen in skin, followed by
type III and type IV, which contribute for the stability of the epidermis
and are responsible for its tensile strength. In this work, it was veriﬁedTable 3
Skin inﬂammatory and granulation tissue histological analysis in the presence of NT, collagen an
Masson's Trichrome staining. Symbols represent:− absence or no alterations, + presence b10
Day 3
PBS collagen
Control Diabetic Control D
Inﬂammation status
– PMN ++ +++ ++ +
– Lymphocytes + ++ + +
– Plasma cells − − − −
– Fibrin b N N b
Repair
– Fibroblasts b N b N
Collagen matrix
– Loose − − − +
– Scar − − − −that all the treatments signiﬁcantly increased the expression of COL1A1,
COL1A2 and COL3A1 in the skin of diabetic mice. On the contrary, treat-
ments with collagen (alone or loaded with NT) in the skin of control
mice led to a decrease in the expression of these genes. Recent studies
show that a decrease in the expression of type III collagen, in early gran-
ulation tissue, promotes myoﬁbroblast differentiation and an increase
in scar deposition in cutaneous wounds [40]. Although these results
were not reproduced by the measured hydroxyproline levels, results
from histopathological analysis showed an increase in the amount of
ﬁbroblasts and loose collagenmatrix in the treated diabetic skin already
at day 3.
After complete healing (fd), the inﬂammatory process in control
skin has already been mostly concluded, as expected. The decrease in
theMMP-9 protein levels, in diabetic skin, contributes to the proteolytic
degradation of the ECMand consequently to repair and remodel cutane-
ous wounds. During the re-epithelialization and remodeling phases, the
initial ECM formed is being replaced by collagenous matrix [41]. Fibro-
blasts promote re-epithelialization by the production of ECM proteins
such as collagen [42]. Fibroblast accumulation at the wound site wasd NT–loaded collagen dressings treated control and diabetic wounds at day 3, by H&E and
%, ++ presence 10%–50%, +++ presence N50%; b not relevant, N predominant.
NT NT–loaded collagen
iabetic Control Diabetic Control Diabetic
++ + ++ +
+ + ++ ++
− − − −
N b N b
b N b N
+ + ++ ++
− + − −
Table 4
Skin inﬂammatory and granulation tissue histological analysis in thepresence ofNT, collagen andNT–loaded collagendressings treated control anddiabeticwounds after complete healing
(fd), by H&E and Masson's Trichrome staining. Symbols represent:− absence or no alterations, + presence b10%, ++ presence 10%–50%, +++ presence N50%.
Complete wound healing (fd)
PBS Collagen NT NT–loaded collagen
Control Diabetic Control Diabetic Control Diabetic Control Diabetic
Inﬂammation status
– PMN − + − − − − − +
– Lymphocytes + + + ++ + +++ + ++
– Plasma cells − − − − − − − −
– Fibrin − − − − − − − −
Repair
– Fibroblasts ++ + + ++ + ++ + +++
Collagen matrix
– Loose + + + ++ ++ +++ ++ +++
– Scar + + + ++ + + + ++
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out NT), enhancing COL1A2 and COL3A1 expression and collagen depo-
sition and consecutively the formation of a more organized loose
collagen matrix, as observed by both H&E and Masson's Trichrome
staining. However, a more prominent scar is evident when these treat-
mentswith collagen are applied in diabetic skinwhen comparedwith the
treatment with NT alone (without the collagen support). This may indi-
cate that NT stimulates wound closure with a better esthetic appearance.
A similar matrix/dressing effect was previously observed in our group
after application of a chitosan derivative (5-methylpirrolidinone) for the
treatment of diabetic wounds [37].
5. Conclusions
The results obtained in this work show that NT–loaded collagen
dressings are effective as wound-healing accelerators in diabetic mice,
at day 3 post-wounding (inﬂammatory phase), reducing the inﬂamma-
tory inﬁltrate in the early phase of healing and the proteolytic degrada-
tion of ECM by MMP-9. Moreover, NT–loaded collagen stimulated
ﬁbroblast accumulation in tissue granulation, collagen expression and
deposition at thewound site, which lead to the production of amore or-
ganized collagen matrix. On the contrary, the treatment with NT alone
presented a lower inﬂammatory potential however, it stimulated theTable 5
Summary of protein expression in wounded control and diabetic skin, at day 3 post-wounding
Day Cytokine/growth factor Control mice Diab
3 TNF-α = ↑ NT
IL-1β ↓ NT, Col+NT =
MMP-9 ↓ Col+NT ↓ Col
TGFβ1 ↑ NT ↑ Col
TGFβ3 ↑ NT ↑ Col
COL1A1 ↓ Col, Col+NT ↑ Col
COL1A2 ↓ Col, Col+NT ↑ Col
Col+
COL3A1 ↓ Col, Col+NT ↑ Col
fd TNF-α ↓ NT, Col+NT ↑ Col
Col+
IL-1β = =
MMP-9 ↓ Col, NT,
Col+NT
↓ Col
Col+
TGFβ1 ↑ Col, NT,
Col+NT
=
TGFβ3 = =
COL1A1 ↑ Col, NT,
Col+NT
↓ NT
COL1A2 ↑ Col, NT,
Col+NT
↑Col
COL3A1 ↑ Col, NT,
Col+NT
↑Col
= means no differences; ↓means signiﬁcant decrease; ↑means signiﬁcant increase.expression of all of the collagen types studied in thiswork. Special atten-
tion was given to the effect of each treatment at different time points
(0, 3, 10days post-wounding and after complete healing) which corre-
spond to different stages of thewound healing process. Table 5 summa-
rizes the cytokine expression in wounded non-diabetic and diabetic
skin, at day 3 and after complete healing. All together these results indi-
cate that NT can enhance diabetic wound healing and that its activity
can be even enhanced when it is applied on collagen based dressings.
These effects were particularly evident during the inﬂammatory
phase. Despite of the promising results, the NT–collagen treatment
still led to the formation of a more pronounced scar after complete
healing. Therefore further studies will have to be done to overcome
this issue and to develop a dressing material that can originate im-
proved esthetic results. The promising results obtained in this work
need also to be complemented with human studies to further investi-
gate the potential application of NT–loaded collagen wound dressings
for diabetic foot ulcer treatment.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2013.10.009.
Conﬂict of interest
The authors do not have any conﬂicts of interest.and after complete healing (fd).
etic mice Cell type that produce this protein
, ↓Col+NT Macrophages, ﬁbroblasts
Macrophages, epithelial cells
, Col+NT Fibroblasts, keratinocytes, macrophages, endothelial cells
, NT Macrophages, PMN, ﬁbroblasts, keratinocytes, epithelial cells
, NT Macrophages, PMN, ﬁbroblasts, keratinocytes, epithelial cells
, NT Fibroblasts
, NT,
NT
Fibroblasts
, NT Fibroblasts
, NT,
NT
Macrophages, ﬁbroblasts
Macrophages, epithelial cells
, NT,
NT
Fibroblasts, keratinocytes, macrophages, endothelial cells
Macrophages, PMN, ﬁbroblasts, keratinocytes, epithelial cells
Macrophages, PMN, ﬁbroblasts, keratinocytes, epithelial cells
Fibroblasts
, Col+NT Fibroblasts
, Col+NT Fibroblasts
43L.I.F. Moura et al. / Biochimica et Biophysica Acta 1842 (2014) 32–43Acknowledgements
This work was ﬁnancially supported by COMPETE, FEDER and
Fundação para a Ciência e Tecnologia (FCT-MEC) under contract PTDC/
SAU-MII/098567/2008, PTDC/SAU FAR/121109/2010, PEst-C/EQB/
UI0102/2011 and PEst-C/SAU/LA0001/2013-2014, in addition to the
RIMADEL — Rede Iberoamericana de Nuevos Materiales para el Diseño
de Sistemas Avanzados de Liberación de Fármacos en Enfermidades
de Alto Impacto Socioeconómico, EFSD/JDRF/Novo Nordisk European
Programme in Type 1 Diabetes Research and Sociedade Portuguesa de
Diabetologia (SPD).
Liane I. F.Moura, AnaM. A. Dias and Ermelindo Leal acknowledge FCT-
MEC for their fellowships SFRH/BD/60837/2009, SFRH/BPD/40409/2007
and SFRH/BPD/46341/2008, respectively.
References
[1] J.E. Shaw, R.A. Sicree, P.Z. Zimmet, Global estimates of the prevalence of diabetes for
2010 and 2030, Diabetes Res. Clin. Pract. 87 (2010) 4–14.
[2] A. Tellechea, E. Leal, A. Veves, E. Carvalho, Inﬂammatory and angiogenic abnormal-
ities in diabetic wound healing: role of neuropeptides and therapeutic perspectives,
Open Circ. Vasc. J. 3 (2010) 43–55.
[3] L. Silva, E. Carvalho, M.T. Cruz, Role of neuropeptides in skin inﬂammation and its
involvement in diabetic wound healing, Expert. Opin. Biol. Ther. 10 (2010)
1427–1439.
[4] L. Pradhan, C. Nabzdyk, N.D. Andersen, F.W. LoGerfo, A. Veves, Inﬂammation and
neuropeptides: the connection in diabetic wound healing, Expert Rev. Mol. Med.
11 (2009) e2.
[5] L.H. Lazarus, M.R. Brown,M.H. Perrin, Distribution, localization and characteristics of
neurotensin binding sites in the rat brain, Neuropharmacology 16 (1977) 625–629.
[6] F. Sundler, R. Hakanson, R.A. Hammer, J. Alumets, R. Carraway, S.E. Leeman, E.A.
Zimmerman, Immunohistochemical localization of neurotensin in endocrine cells
of the gut, Cell Tissue Res. 178 (1977) 313–321.
[7] S.D. Brain, Sensory neuropeptides: their role in inﬂammation and wound healing,
Immunopharmacology 37 (1997) 133–152.
[8] K. Kalafatakis, K. Triantafyllou, Contribution of neurotensin in the immune and neu-
roendocrine modulation of normal and abnormal enteric function, Regul. Pept. 170
(2011) 7–17.
[9] J.R. Scott, R.N. Tamura, P. Muangman, F.F. Isik, C. Xie, N.S. Gibran, Topical substance P
increases inﬂammatory cell density in genetically diabetic murine wounds, Wound
Repair Regen. 16 (2008) 529–533.
[10] L. Pradhan, X. Cai, S. Wu, N.D. Andersen, M. Martin, J. Malek, P. Guthrie, A. Veves,
F.W. Logerfo, Gene expression of pro-inﬂammatory cytokines and neuropeptides
in diabetic wound healing, J. Surg. Res. 167 (2011) 336–342.
[11] S.M. Sweitzer, S.A. Fann, T.K. Borg, J.W. Baynes, M.J. Yost, What is the future of
diabetic wound care? Diabetes Educ. 32 (2006) 197–210.
[12] P.B. Malafaya, G.A. Silva, R.L. Reis, Natural-origin polymers as carriers and scaffolds
for biomolecules and cell delivery in tissue engineering applications, Adv. Drug
Deliv. Rev. 59 (2007) 207–233.
[13] S.A. Sell, P.S. Wolfe, K. Garg, J.M. McCool, I.A. Rodriguez, G.L. Bowlin, The use of
natural polymers in tissue engineering: a focus on electrospun extracellular matrix
analogues, Polym. Adv. Technol. 2 (2010) 522–553.
[14] B.V. Slaughter, S.K. Shahana, O.Z. Fisher, A. Khademhosseini, N.A. Peppas, Hydrogels
in regenerative medicine, Adv. Mater. 21 (2009) 3307–3329.
[15] L.I. Moura, A.M. Dias, E. Carvalho, H.C. de Sousa, Recent advances on the develop-
ment of wound dressings for diabetic foot ulcer treatment—a review, Acta Biomater.
9 (2013) 7093–7114.
[16] O. Singh, S.S. Gupta, M. Soni, S. Moses, S. Shukla, R.K. Mathur, Collagen dressing
versus conventional dressings in burn and chronic wounds: a retrospective study,
J. Cutan. Aesthet. Surg. 4 (2011) 12–16.
[17] L. Cen, W. Liu, L. Cui, W. Zhang, Y. Cao, Collagen tissue engineering: development of
novel biomaterials and applications, Pediatr. Res. 63 (2008) 492–496.
[18] F. Antonio, R. Guillem, T. Sonia, M. Clara, G. Piergiorgio, C. Valeria, C. Gianluca, T.
Tzanov, Cross-linked collagen sponges loadedwith plant polyphenols with inhibito-
ry activity towards chronic wound enzymes, Biotechnol. J. 6 (2011) 1208–1218.
[19] J.F. Mano, G.A. Silva, H.S. Azevedo, P.B. Malafaya, R.A. Sousa, S.S. Silva, L.F. Boesel, J.M.
Oliveira, T.C. Santos, A.P.Marques, N.M. Neves, R.L. Reis, Natural origin biodegradable
systems in tissue engineering and regenerative medicine: present status and some
moving trends, J. R. Soc. Interface. 4 (2007) 999–1030.
[20] V. Arul, J.G. Masilamoni, E.P. Jesudason, P.J. Jaji, M. Inayathullah, D.G. Dicky John, S.
Vignesh, R. Jayakumar, Glucose oxidase incorporated collagen matrices for dermalwound repair in diabetic rat models: a biochemical study, J. Biomater. Appl. 26
(2012) 917–938.
[21] N. Adhirajan, N. Shanmugasundaram, S. Shanmuganathan, M. Babu, Collagen-based
wound dressing for doxycycline delivery: in-vivo evaluation in an infected excision-
al wound model in rats, J. Pharm. Pharmacol. 61 (2009) 1617–1623.
[22] F. Manizate, A. Fuller, C. Gendics, J. Lantis, A prospective, single-center, nonblinded,
comparative, postmarket clinical evaluation of a bovine-derived collagen with ionic
silver dressing versus a carboxymethylcellulose and ionic silver dressing for the
reduction of bioburden in variable-etiology, bilateral lower-extremity wounds,
Adv. Skin Wound Care 25 (2012) 220–225.
[23] K. Kawai, S. Suzuki, Y. Tabata, Y. Nishimura, Accelerated wound healing through the
incorporation of basic ﬁbroblast growth factor-impregnated gelatin microspheres
into artiﬁcial dermis using a pressure-induced decubitus ulcer model in genetically
diabetic mice, Br. J. Plast. Surg. 58 (2005) 1115–1123.
[24] N. Kanda, N. Morimoto, A.A. Ayvazyan, S. Takemoto, K. Kawai, Y. Nakamura, Y.
Sakamoto, T. Taira, S. Suzuki, Evaluation of a novel collagen–gelatin scaffold for achiev-
ing the sustained release of basic ﬁbroblast growth factor in a diabetic mouse model, J.
Tissue Eng. Regen. Med. (2012), http://dx.doi.org/10.1002/term.1492 (in press).
[25] L.P. Nabzdyk, S. Kuchibhotla, P. Guthrie, M. Chun, M.E. Auster, C. Nabzdyk, S. Deso, N.
Andersen, C. Gnardellis, F.W. LoGerfo, A. Veves, Expression of neuropeptides and cy-
tokines in a rabbit model of diabetic neuroischemic wound healing, J. Vasc. Surg. 58
(2013) 766–775.
[26] W.Wang, S. Lin, Y. Xiao, Y. Huang, Y. Tan, L. Cai, X. Li, Acceleration of diabetic wound
healing with chitosan-crosslinked collagen sponge containing recombinant human
acidic ﬁbroblast growth factor in healing-impaired STZ diabetic rats, Life Sci. 82
(2008) 190–204.
[27] A. Sarkar, S. Tatlidede, S.S. Scherer, D.P. Orgill, F. Berthiaume, Combination of stromal
cell-derived factor-1 and collagen-glycosaminoglycan scaffold delays contraction
and accelerates reepithelialization of dermal wounds in wild-type mice, Wound
Repair Regen. 19 (2011) 71–79.
[28] R. Parenteau-Bareil, R. Gauvin, F. Berthod, Collagen-based biomaterials for tissue
engineering applications, Materials 3 (2010) 1863–1887.
[29] A. Yahyouche, X. Zhidao, J.T. Czernuszka, A.J. Clover, Macrophage-mediated degra-
dation of crosslinked collagen scaffolds, Acta Biomater. 7 (2011) 278–286.
[30] K.S. Rho, L. Jeong, G. Lee, B.M. Seo, Y.J. Park, S.D. Hong, S. Roh, J.J. Cho,W.H. Park, B.M.
Min, Electrospinning of collagen nanoﬁbers: effects on the behavior of normal
human keratinocytes and early-stage wound healing, Biomaterials 27 (2006)
1452–1461.
[31] N.S. Gibran, Y.C. Jang, F.F. Isik, D.G. Greenhalgh, L.A. Mufﬂey, R.A. Underwood, M.L.
Usui, J. Larsen, D.G. Smith, N. Bunnett, J.C. Ansel, J.E. Olerud, Diminished neuropep-
tide levels contribute to the impaired cutaneous healing response associated with
diabetes mellitus, J. Surg. Res. 108 (2002) 122–128.
[32] G. Properzi, S.F. Villa, G. Poccia, P. Aloisi, X. Gu, G. Terenghi, J.M. Polak, Early increase
precedes a depletion of VIP and PGP-9.5 in the skin of insulin-dependent diabetics—
correlation between quantitative immunohistochemistry and clinical assessment of
peripheral neuropathy, J. Pathol. 169 (1993) 269–277.
[33] H. Galkowska, U. Wojewodzka, W.L. Olszewski, Chemokines, cytokines, and growth
factors in keratinocytes and dermal endothelial cells in themargin of chronic diabet-
ic foot ulcers, Wound Repair Regen. 14 (2006) 558–565.
[34] R. Blakytny, E. Jude, The molecular biology of chronic wounds and delayed healing
in diabetes, Diabet. Med. 23 (2006) 594–608.
[35] E. Black, J. Vibe-Petersen, L.N. Jorgensen, S.M. Madsen, M.S. Agren, P.E. Holstein, H.
Perrild, F. Gottrup, Decrease of collagen deposition in wound repair in type 1 diabe-
tes independent of glycemic control, Arch. Surg. 138 (2003) 34–40.
[36] S.L. Hansen, C.A. Myers, A. Charboneau, D.M. Young, N. Boudreau, HoxD3 accelerates
wound healing in diabetic mice, Am. J. Pathol. 163 (2003) 2421–2431.
[37] L.I.F. Moura, A.M.A. Dias, E.C. Leal, L. Carvalho, H.C. de Sousa, E. Carvalho,
Chitosan-based dressings loadedwithneurotensin-an efﬁcient strategy to improve
early diabetic wound healing, Acta Biomater (2013), http://dx.doi.org/10.1016/
j.actbio.2013.09.040 (in press).
[38] R. Lobmann, A. Ambrosch, G. Schultz, K.Waldmann, S. Schiweck, H. Lehnert, Expres-
sion of matrix-metalloproteinases and their inhibitors in thewounds of diabetic and
non-diabetic patients, Diabetologia 45 (2002) 1011–1016.
[39] P. Beldon, Basic science of wound healing, Surgery 28 (2010) 409–412.
[40] S.W. Volk, Y. Wang, E.A. Mauldin, K.W. Liechty, S.L. Adams, Diminished type III
collagen promotes myoﬁbroblast differentiation and increases scar deposition in
cutaneous wound healing, Cells Tissues Organs 194 (2011) 25–37.
[41] A.J. Singer, R.A. Clark, Cutaneous wound healing, N. Engl. J. Med. 341 (1999)
738–746.
[42] F. Al-Mulla, S.J. Leibovich, I.M. Francis, M.S. Bitar, Impaired TGF-beta signaling and a
defect in resolution of inﬂammation contribute to delayed wound healing in a
female rat model of type 2 diabetes, Mol. Biosyst. 7 (2011) 3006–3020.
[43] L. Espinoza, A.. Sosnik, M.R. Fontanilla, Development and Preclinical Evaluation of
Acellular Collagen Scaffolding and Autologous Artiﬁcial Connective Tissue in the Re-
generation of Oral Mucosa Wounds, Tissue Engineering: Part A 5 (2010)
1667–1679.
